Drug Trial Radar · NCT05119335
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
120
Actual
Start
Oct 26, 2021
Primary completion
Aug 22, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- NiKang Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Conditions
- ccRCC
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Kidney Neoplasms
- Renal Cancer
- Renal Neoplasms
- Recurrent Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Hypoxia
- Renal Cell Carcinoma
- Hypoxia Inducible Factor (HIF)
- HIF2α Inhibitor
- Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
- Hypoxia Inducible Factor 2α (HIF-2α)
- Clear Cell
Interventions
Oral NKT2152Drug
Oral HIF2α inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)Time frame: 21 days
- Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)Time frame: Approximately 2 years
- Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)Time frame: Approximately 1 year
- Recommended Phase 2 Dose (RP2D)Time frame: Approximately 1 year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
UCLA
Los Angeles, California
Sarah Cannon Research Institute
Denver, Colorado
Emory University
Atlanta, Georgia
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
National Cancer Institute
Bethesda, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Nebraska Cancer Specialists
Omaha, Nebraska
University of Oklahoma
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.